A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant
A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.
대표청구항▼
1. An ocular insert for use in an eye, the eye having upper and lower lids extendable along an anterior eye surface with an optical zone therebetween, the insert comprising: a first structure disposable along the anterior surface of the eye of a patient outside the optical zone of the eye, the first
1. An ocular insert for use in an eye, the eye having upper and lower lids extendable along an anterior eye surface with an optical zone therebetween, the insert comprising: a first structure disposable along the anterior surface of the eye of a patient outside the optical zone of the eye, the first structure comprising an annulus formed of configuration-altering material;a second structure supported by at least a portion of the first structure, the second structure adapted to provide engagement between the insert and eye tissue surrounding the insert, wherein the second structure has an anterior surface and a posterior surface, the posterior surface configured to contact the anterior surface of the eye, wherein the second structure completely surrounds the portion of the first structure in a cross-section taken from the anterior surface to the posterior surface of the second structure, and wherein the first structure helps maintain the insert in contact with the eye for a plurality of days;at least one drug disposed on or embedded into the second structure so as to release a safe and therapeutically effective quantity of the drug from the second structure to the eye for each of the plurality of days; andwherein the first structure comprises a configuration-altering, non-biodegradable material that activates after the ocular insert is inserted onto the anterior surface of the eye so as to cause each of the first and the second structures of the ocular insert to reconfigure from an initial, pre-insertion configuration to a second, post-insertion configuration that conforms the first and second structures of the ocular insert to the anterior surface of the eye to maintain the ocular insert in contact with the eye for the plurality of days. 2. The ocular insert of claim 1, wherein the at least one drug is further disposed on or in the first structure. 3. The ocular insert of claim 1, wherein the plurality of days comprises at least 30 days. 4. The ocular insert of claim 1, wherein the drug comprises one or more members selected from the group consisting of: steroids, anti-inflammatories, antibiotics, glaucoma treatment medications, antihistamines, and dry eye medications. 5. The ocular insert of claim 1, wherein the drug comprises one or more members selected from the group consisting of: a steroid selected from the group consisting of at least one of glucocorticoids, aprogestins, amineralocorticoids, corticosteroids, cortisone, hydrocortisone, prednisone, prednisolone, methylprednisone, triamcinolone, fluoromethalone, dexamethasone, medrysone, betamethasone, loteprednol, fluocinolone, flumethasone, rimexolone mometasone, androgens, testosterone, methyltestosterone, and danazol;a non-steroidal anti-inflammatory (NSAID) selected from the group consisting of at least one of piroxicam, aspirin, salsalate, diflunisal, ibuprofen, ketoprofen, nabumetone, piroxicam, naproxen, diclofenac, indomethacin, sulindac, tolmetin, etodolac, ketorolac, oxaprozin, and celecoxib;an antibiotic selected from the group consisting of at least one of amoxicillin, penicillin, sulfa drugs, erythromycin, streptomycin, tetracycline, clarithromycin, terconazole, azithromycin, bacitracin, ciprofloxacin, evofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, aminoglycosides, tobramycin, gentamicin, polymyxin B combinations, wherein the polymyxin B combinations are selected from the group consisting of polymyxin B/trimethoprim, polymyxin B/bacitracin, and polymyxin B/neomycin/gramicidin;a glaucoma treatment medication selected from the group consisting of at least one of beta-blockers, mitotics, carbonic anhydrase inhibitors, prostaglandins, prostaglandin analogs, seretonergics, muscarinics, dopaminergic agonists, and adrenergic agonists, wherein the beta-blockers are selected from the group consisting of timolol, betaxolol, levobetaxolol, and carteolol,wherein the miotics are selected from the group consisting of pilocarpine,wherein the carbonic anhydrase inhibitors are selected from the group consisting of brinzolamide, and dorzolamide,wherein the prostaglandin analogs are selected from the group consisting of travoprost, bimatoprost, and latanoprost, andwherein the adrenergic agonists are selected from the group consisting of apraclonidine, and brimonidine;an antihistamine and mast cell stabilizer selected from the group consisting of at least one of olopatadine and epinastine;an acute care anti-allergenic product selected from the group consisting of at least one of ketorolac tromethamine, ketotifen fumarate, loteprednol, epinastine HCl, emedastine difumarate, azelastine hydrochloride, olopatadine hydrochloride, and ketotifen fumarate;a chronic care anti-allergenic product selected from the group consisting of at least one of pemirolast potassium, nedocromil sodium, lodoxamide tromethamine, and cromolyn sodium;a dry eye medication selected from the group consisting of cyclosporinel; andan anesthetic. 6. The ocular insert of claim 1, wherein the drug is hydrophilic, and wherein the drug is dispersed in a hydrophilic polymer. 7. The ocular insert of claim 1, wherein the drug is hydrophobic, and wherein the insert comprises surfactants to increase the drug solubility. 8. The ocular insert of claim 1, wherein the drug is hydrophobic, and wherein the insert comprises an elution rate decrease material, the elution rate decrease material comprising a coating over the drug, a component of a delivery matrix and/or a coating on the delivery matrix. 9. The ocular insert of claim 1, wherein the annulus has a local thickening along at least one portion of the annulus. 10. The ocular insert of claim 1, wherein the annulus has at least one arc radially offset from the annulus, and a plurality of radial members extending between the at least one arc and annulus. 11. The ocular insert of claim 1, wherein the annulus is a serpentine annulus having radially inward portions interspersed with radially outward portions. 12. The ocular insert of claim 1, wherein the annulus has inner and outer edges, at least one of the edges being atraumatically shaped to avoid sharp-edge irritation of the eye. 13. The ocular insert of claim 1, wherein the annulus has a non-planar eye-engagement surface. 14. The ocular insert of claim 1, further comprising an actuatable delivery instrument having a receptacle for releasably receiving the insert so as to support the insert during positioning of the insert, wherein actuation of the delivery instrument when at least a portion of the insert engages the eye between a sclera and a lid atraumatically releases the insert from the receptacle. 15. An insert as in claim 1, wherein the initial configuration is a first shape and the second configuration is a second shape. 16. An insert as in claim 1, wherein the material of the first structure is thermally activated. 17. An insert as in claim 1, wherein the material of the first structure is activated through heat imparted to the insert through the eye or eyelids. 18. An insert as in claim 1, wherein the drug comprises a prostaglandin analog. 19. An insert as in claim 1, further comprising a coating on at least one of the first and second structures. 20. The ocular insert of claim 1, wherein the insert comprises an elution rate altering material. 21. The ocular insert of claim 20, wherein the drug comprises the elution rate altering material. 22. An insert as in claim 1, wherein the drug comprises at least one of bimatoprost and latanoprost. 23. An insert as in claim 1, wherein the first structure has a circumferential length that forms a diameter sized to fit around and remain outside the cornea of the eye. 24. An insert as in claim 23, wherein the eye tissue surrounding the insert comprises the sclera and/or at least one of the upper and lower eyelids. 25. An insert as in claim 1, wherein the second structure has a cross-sectional shape that is rounded or beveled. 26. An insert as in claim 1, wherein the first structure comprises a material that determines an overall shape of the ocular insert and provides structural support to maintain the ocular insert in contact with the eye for a plurality of days. 27. An insert as in claim 26, wherein the material of the first structure is a polypropylene suture or a nylon suture. 28. An insert as in claim 27, wherein the second structure is a silicone matrix. 29. An insert as in claim 28, wherein the suture threads through an interior of the silicone matrix. 30. An insert as in claim 1, wherein the second structure comprises a plurality of cushioning structures, each cushioning structure completely surrounding a discrete portion of a length of the first structure.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (115)
Lance Wolfgang (Obernburg DEX), Active agent containing solid structures for prolonged release of active agents.
Brightman ; II Alan H. (Champaign IL) Theodorakis Michael C. (Champaign IL), Biodegradable ocular insert for controlled delivery of ophthalmic medication.
Koller Bruno (Hasengasse 23 6 Frankfurt am Main DEX) Kilb Friedrich (Scheidwald Str. 43 6 Frankfurt am Main DEX), Contact lens eyeball centering support of soft material for use in conjunction with hard contact lens.
Eury Robert P. (Cupertino CA) Garguilo Darlene (Fremont CA) Villareal Plaridel (San Jose CA), Drug loaded polymeric material and method of manufacture.
Ahmed, Salah U.; Chowdhury, Tahseen A.; Luo, Yi, Flexible, compressed intravaginal rings, methods of making and using the same, and apparatus for making the same.
Carvalho,Ricardo Azevedo Pontes de; Murphree,Alan Linn; Schmitt,Edward E., Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues.
Rosenthal Kenneth J. (4 White Pine La. Kings Point NY 11023-1704), Method and device for deep pressurized topical, fornix applied “nerve block”anesthesia.
Parel Jean-Marie (Miami FL) Parrish Richard (Miami FL) Portugal Lourdes (Miami FL) Olsen Karl R. (Miami FL), Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agen.
de Juan, Jr., Eugene; Boyd, Stephen; Reich, Cary; Rapacki, Alan; Gifford, III, Hanson S.; Deem, Mark, Nasolacrimal drainage system implants for drug therapy.
Darougar Sohrab,GBX ; Weiner Alan L. ; Bhatt Padmanabh Pravinchandra ; Raul Victor Albert ; Gantner David Clayton, Ocular insert with anchoring protrusions.
Gale Robert M. (Mt. View CA) Ben-Dor Monique (Palo Alto CA) Keller Nancy (Palo Alto CA), Ocular therapeutic system for dispensing a medication formulation.
Cohen Edward M. (Beaumont PA FRX) Grim Wayne M. (Doylestown PA) Harwood Richard J. (Philadelphia PA) Mehta Gunvant N. (Lansdale PA), Solid state ophthalmic medication.
Withers Stanley J. (4701 San Leandro St. Oakland CA 94601) Schneiderman Gary E. (640 Mandarin La. Walnut Creek CA 94598) Little ; Jr. William M. (1059 Norwood Ave. Oakland CA 94610), Split carrier for eyelid sensor and the like.
Folkman Moses J. (18 Chathman Cir. Brookline MA 02146) Langer ; Jr. Robert S. (1200 Commonwealth ; Apt. 2 Allston MA 02134), Systems for the controlled release of macromolecules.
Shell John W. (Hillsborough CA) Gale Robert M. (Mountain View CA), Topical composition containing steroid in two forms released independently from polymeric carrier.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.